

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶: C12N 5/06, A61K 35/14	A1	(11) International Publication Number: WO 99/50391 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/EP99/02106 (22) International Filing Date: 29 March 1999 (29.03.99) (30) Priority Data: 98400742.7 30 March 1998 (30.03.98) EP (71) Applicant (for all designated States except US): I.D.M. IMMUNO-DESIGNED MOLECULES [FR/FR]; 172, rue de Charonne, F-75011 Paris (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): BARTHOLEYNS, Jacques [FR/FR]; 10, rue du Royaume, F-91440 Bures-sur-Yvette (FR). CHOKRI, Mohamed [MA/FR]; 69, rue Haxo (No. 10), F-75020 Paris (FR). LATOUR, Nathalie [BE/BE]; 143, rue Ernest Laurent, B-1420 Braine l'Alleud (BE). (74) Agents: GROSSET-FOURNIER, Chantal et al.; Grosset-Fournier & Demachy, 20, rue de Maubeuge, F-75009 Paris (FR).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: STIMULATED MONOCYTE DERIVED CELLS, THEIR PREPARATION AND USES (57) Abstract <p>The invention relates to stimulated monocyte derived cells presenting the following characteristics: 1) increased release, with respect to normal monocyte derived cells, of for instance PDGF (platelet derived growth factor), and increased presence, on their membranes, with respect to normal monocyte derived cells, of for instance CD1α, and/or. 2) presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division. These stimulated monocyte derived cells can be the active substance of pharmaceutical compositions.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

STIMULATED MONOCYTE DERIVED CELLS, THEIR PREPARATION AND USES

5

The invention relates to stimulated monocyte derived cells, processes for their preparation, and pharmaceutical compositions containing the same.

10

15

It has long been established that macrophages have a primary role in wound and tissue repair (see for example Wong and Wahl, Inflammation and repair, in Handbook of Exp Pharmacol, 95:509-548, 1990). They are inducers and regulators of healing ; they favor angiogenesis and recruit cells which will complete wound repair. After a tissue has been injured (burn, ulcers, wounds, trauma, mucosal damage, infarcts or even reconstructive surgery), macrophages called locally clean the wound by elimination of the necrotic debris formed by dead cells (by phagocytosis and proteolysis). At the same time macrophages, activated locally by this phagocytosis, actively release growth factors, monokines and chemokines. These autologous factors stimulate surrounding cells to multiply and to migrate towards the wound and to replace the dead cells.

20

Macrophages play a major role in the antitumoral response, and they are able to be activated by immunological activators against cancer cells (Adams D. and Hamilton T.: "Activation of macrophages for tumor cell kill: effector mechanism and regulation"; in Heppner & Fulton (eds), Macrophages and cancer. CRC Press, 1988, p. 27 ; Fidler M. Macrophages and metastases. A biological approach to cancer therapy. Cancer Res. 45: 4714, 1985).

25

Furthermore, macrophages, or other cells derived from monocytes or from their precursors, with their strong capacity for endocytosis, digestion, and surface antigen presentation, are capable of inducing a specific immune response. In this way, they represent good candidates for the preparation of vaccines, and more specifically cellular autologous vaccines.

30

Monocytes derived cells (MDCs) are immune cells such as obtained by culture of blood mononuclear cells in non adherent gas permeable plastic or Teflon bags for 5 to 10 days at 37°C in O₂/CO₂ atmosphere. Their culture medium (RPMI, IMDM,

AIM5 (Gibco) or X-VIVO (Biowhittaker)) contains eventually cytokines or ligands as defined in patents n° PCT/EP93/01232, n° WO94/26875 or EP 97/02703 or in the articles mentioned below :

5 . "Autologous lymphocytes prevent the death of monocytes in culture and promote, as do GM-CSF, IL-3 and M-CSF, their differentiation into macrophages". (Lopez M., Martinache Ch., Canepa S., Chokri M., Scotto F., Bartholeyns J.; J. of Immunological Methods, 159: 29-38, 1993) ;

10 . "Immune therapy with macrophages: Present status and critical requirements for implementation" (Bartholeyns J., Romet-Lemonne J-L., Chokri M., Lopez M. ; Immunobiol., 195: 550-562, 1996) ;

15 . "In vitro generation of CD83⁺ human blood dendritic cells for active tumor immunotherapy" (Thurnher M., Papesh C., Ramoner R., Gastlt G. and al. ; Experimental Hematology, 25:232-237, 1997) ;

20 . "Dendritic cells as adjuvants for immune-mediated resistance to tumors" (Schuler G. and Steinman R. M. ; J. Exp. Med., 186:1183-1187, 1997).

All these patent applications and articles are included herein for references.

25 They can be activated by INF- γ at the end of culture to obtain in particular cytotoxic macrophages. They can be centrifuged to be concentrated and purified before resuspension in isotonic solution.

30 Monocytes derived cells (MDCs) can either be killer macrophages, phagocytosing cells, growth factors and cytokines releasing cells, or dendritic cells according to their conditions of differentiation. Dendritic cells can for example be obtained as described in "In vitro generation of CD83⁺ human blood dendritic cells for active tumor immunotherapy" (Thurnher M., Papesh C., Ramoner R., Gastlt G. and al. ; Experimental Hematology, 25:232-237, 1997) and "Dendritic cells as adjuvants for immune-mediated resistance to tumors" (Schuler G. and Steinman R. M.; J. Exp. Med., 186:1183-1187, 1997), and EP n° 97/02703.

Mature dendritic cells are very potent antigen presenting cells to initiate an immune response. The dendritic cells can be characterized by the induction of T cell proliferation and by their phenotype (presence of CD80, CD86, CD83, MHC-I, MHC-II on their membranes).

5 The dendritic cells play an important role, but are difficult to obtain in large quantities, necessary for therapeutic purpose in particular because of the required presence of multiple cytokines. Moreover, the dendritic cells obtained according to standard procedures are not stimulated and therefore do not present direct anti-tumoral or tissue repair properties.

10 One of the aim of the invention, is to provide stimulated monocyte derived cells having enhanced biological activities as described above, when compared to monocyte derived cells described until now.

Another aim of the invention is to provide processes for the preparation of said stimulated monocyte derived cells.

15 Another aim of the invention is to provide new pharmaceutical compositions containing said stimulated monocyte derived cells.

Another aim of the invention is to provide new methods for the treatment of tissue injuries.

20 Another aim of the invention is to provide new methods for the treatment or vaccination against tumors or infectious (bacterial or viral) diseases.

Another aim of the invention is to provide new methods for gene therapy.

The invention relates to stimulated monocyte derived cells presenting the following characteristics:

25 1) - increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides, proteins or compounds:

- . PDGF (platelet derived growth factor)
- . IGF1 (insulin growth factor)
- . MDGF (macrophage derived growth factor)
- . bFGF (basic fibroblast growth factor)
- 30 . GM-CSF (granulocyte macrophage - colony stimulating factor)
- . heat shock or stress proteins,
- . chemokines and monokines such as IL12 and IFN γ

- . enzymes or enzyme inhibitors,
- . complement components,
- . transfer proteins,
- . peroxides, NO (nitrous oxide),
- 5 . bioactive lipids,
- . hormones,

and

- increased presence, on their membranes, with respect to normal monocyte derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40,

and/or

2) presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

15 The expression normal monocyte derived cells correspond to monocytes cultured in defined media or in the presence of cytokines which have not been specifically stressed and therefore which do not release increased levels of immunostimulatory proteins or compounds and simultaneously do not express markedly increased levels of MHC and accessory molecules on their membranes.

20 NO is usually not released due to NO synthase suppression, but, in the case of the invention, NO synthase is desinhibited which causes release of NO.

Monocytes derived cells can be obtained for instance from blood derived monocytes purified and cultured in the presence of GM-CSF and another cytokine, such as IL-4 or IL-13.

25 The invention relates more particularly to stimulated monocyte derived cells as described above, wherein the released polypeptides, proteins and compounds are those listed on Table 1.

According to an advantageous embodiment, the activation markers are present in an amount of at least about 1000 molecules/cells.

30 This can be measured by flow cytometry.

In a particular embodiment of the invention, the monocyte derived cells as described above, contain exogenous compounds in their cytoplasm such as drugs, protein, growth factors of interest.

In another embodiment, the monocyte derived cells as described above contain in their cytoplasm exogenous DNA coding for a protein of interest.

It should be made clear that depending upon the nature of the physical stress, either the DNA contained in the cytoplasm of said monocyte derived cells remain in the cytoplasm after the physical stress, or there is an uptake of said exogenous DNA by their nucleus which is made possible by the physical stress.

The physically stimulated monocyte derived cells of the invention are particularly suited for vaccination purpose since they express at the same time the antigen introduced, increased membrane levels of MHC molecules and accessory molecules to interact with lymphocytes and they release increased amounts of TH1 type (e.a. IL-12) cytokines.

According to an advantageous embodiment, the stimulated monocyte derived cells of the invention, present the following characteristics:

1) increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides or proteins :

- . PDGF (platelet derived growth factor)
- . IGF1 (insulin growth factor)
- . MDGF (macrophage derived growth factor)
- . bFGF (basic fibroblast growth factor)
- . GM-CSF (granulocyte macrophage - colony stimulating factor)
- . heat shock or stress proteins, such as HSP70, HSP90, GP96,
- . chemokines and monokines such as IL12 and IFN γ

and

- increased presence, on their membranes, with respect to normal monocyte derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40,

and/or

2) presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

According to an advantageous embodiment of the invention, said activation markers are present in an amount of at least about 1000 molecules/cell.

5 This can be measured by flow cytometry.

Advantageous stimulated monocyte derived cells according to the invention present at least one of the following characteristics:

- increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides, proteins or compounds:

- 10 . PDGF
- . IGF1
- . MDGF
- . bFGF
- . GM-CSF
- 15 . heat shock or stress proteins
- . chemokines and monokines such as IL12 and IFN γ
- . enzymes or enzyme inhibitors
- . complement components
- . transfer proteins
- 20 . peroxides, NO (nitrous oxide),
- . bioactive lipids
- . hormones

and

- increased presence, on their membranes, with respect to normal monocyte
25 derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40.

According to an advantageous embodiment of the invention, the above polypeptides, proteins or compounds are present in an amount higher than about
30 1pg/cell/hr, and the above activation markers are present in the range of about 10³ to about 10⁵ molecules/cell.

This can be measured by flow cytometry.

Advantageous stimulated monocyte derived cells of the invention present at least one of the following characteristics:

- increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides or proteins :

- . PDGF
- . IGF1
- . MDGF
- . bFGF
- . GM-CSF
- . heat shock or stress proteins
- . chemokines and monokines such as IL12 and IFN γ

and

- increased presence, on their membranes, with respect to normal monocyte derived cells, of one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40.

According to an advantageous embodiment of the invention, the above polypeptides, proteins or compounds are present in an amount higher than about 1 pg/cell/hr, and the above activation markers are present in the range higher than about 10^3 and particularly of about 10^3 to about 10^5 molecules/cell.

This can be measured by flow cytometry.

The invention relates more particularly to stimulated monocyte derived cells, which present the characteristic of having integrated at least one exogenous nucleic acid in their nucleus in the absence of the monocyte derived cell division.

It is to be reminded that transfer of exogenous nucleic acids in cell nuclei by non viral techniques can be effectively achieved in rapidly dividing cells. In non dividing cells such as those derived from monocytes, the exogenous nucleic acids are internalized in vacuoles or in the cytoplasm, but very low integration in endogenous nucleic acids and expression of the coded peptide occur (< 5%). The physical stimulation of the invention allows migration of the exogenous nucleic acids

internalized from the cytoplasm to the nucleus and therefore enables increased expression of the transgene.

Advantageous stimulated monocyte derived cells according to the invention, present the following characteristics:

5 - increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides, proteins or compounds:

- . PDGF
- . IGF1
- . MDGF
- 10 . bFGF
- . GM-CSF
- . heat shock or stress proteins
- . chemokines and monokines such as IL12 and IFN γ
- . enzymes or enzyme inhibitors
- 15 . complement components
- . transfer proteins
- . peroxides, NO (nitrous oxides),
- . bioactive lipids
- . hormones

20 - and increased presence, on their membranes, with respect to normal monocyte derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, and CD40,

25 - and presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

According to an advantageous embodiment of the invention, the abovesaid polypeptides, proteins or compounds are present in an amount higher than about 1pg/cell/hr, and the abovesaid activation markers are present in the range of about 10³ to about 10⁵ molecules/cell.

30 This can be measured by flow cytometry.

Advantageous stimulated monocyte derived cells of the invention present the following characteristics:

- increased release with respect to normal monocyte derived cells of at least one of the following polypeptides or proteins :

- . PDGF
- . IGF1
- . MDGF
- . bFGF
- . GM-CSF
- . heat shock or stress proteins
- . chemokines and monokines such as IL12 and IFN γ

- and increased presence on their membranes with respect to normal monocyte derived cells of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, and CD40,

- and presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

According to an advantageous embodiment of the invention, the abovesaid polypeptides, proteins or compounds are present in an amount higher than about 1pg/cell/hr, and the abovesaid activation markers are present in the range of about 10^3 to about 10^5 molecules/cell.

The amount of polypeptides, proteins or compounds can be measured by ELISA method and the number of membrane activation markers can be measured by flow cytometry.

The invention also relates to a process for the preparation of monocytes derived cells comprising the step of stimulation of said monocyte derived cells by physical means such as: thermal stress (heating at 40°C to 50°C for at least 30 minutes), pressure change (from about 1 bar to about 0,05 bar, or from about 1 bar to about 10 bars), microwaves, electric shock (about 1 to about 10 s at about 250 mV), or electropulsation.

Thermal stress or heat shock is applied as described in : "Differential induction of stress proteins and functional effects of heat shock in human phagocytes." (Polla B.S., Stubbe H., Kantengwa S., Maridonneau-Parini I., Jacquier-Sarlin M.R. - Inflammation, 19:363-378, 1995) or in "Stress-inducible cellular responses" (Feige U., Morimoto R.I., Yahara I., Polla B.S. - Birkhäuser Verlag (Basel, Boston, Berlin), 492p., 1996).

Microwaves are applied under the following conditions : (5 sec to 5 min) 500 to 750 Watts, repeated 1 to 5 times.

Electropulsation (for instance 5 to 10 square electric pulses of 5 millisecc at 0.3 to 0.8 kV/cm) allows flux of ions and of nucleic acids and/or protein transporters from the cytoplasm through the nucleus pores. This positive flux is stopped after the pulsation and the exogenous nucleic acid is integrated in nuclear DNA ("Specific electroporabilization of leucocytes in a blood sample and application to large volumes of cells"; S. Sixou and J. Teissié ; Elsevier, Biochimica et Biophysica Acta. 1028:154-160, 1990).

Electric shock is applied as described in "Control by Pulse Parameters of Electric Field-Mediated Gene Transfer in Mammalian Cells" (Hendrick W. et al., Biophysical Journal, Vol. 66:524-531, February 1994).

The process for the preparation of stimulated monocyte derived cells of the invention comprises the following steps :

- preparation of monocyte derived cells according to the following method :

- 1) recovery of blood derived mononuclear cells directly from blood apheresis or from blood bag collection, followed if necessary by centrifugation, to eliminate a substantial part of red blood cells granulocytes and platelets, and collection of peripheral blood leukocytes ;
- 2) washing peripheral blood leukocytes obtained at the preceding steps for instance by centrifugation (to remove 90% of platelets, red blood cells and debris) to obtain mononuclear cells ;
- 3) resuspension of the total mononuclear cells (monocytes + lymphocytes) obtained at the preceding step in culture medium (AIM-V, RPMI or IMDM type) at 10^6 to $2 \cdot 10^7$ cells/ml, possibly

completed by cytokines and/or autologous serum, and culture for 5 to 10 days at 37°C under O₂/CO₂ atmosphere in hydrophobic gas permeable bags, to obtain monocyte derived cells and contaminating lymphocytes ;

5 - stimulation of said monocyte derived cells by physical means such as : thermal stress (heating at 40°C to 50°C for at least 30 minutes), pressure change (from about 1 bar to about 0,05 bar, or from about 1 bar to about 10 bars), microwaves, electric shock (about 1 to about 10 s at about 250 mV), or electropulsation for a time sufficient to induce the above-mentioned characteristics.

10 Stimulation of said monocyte derived cells can also be achieved by means of chemicals which cause maturation of said monocyte derived cells, resulting in increased stimulation of cells as described above. Advantageous chemicals are those which are responsible for the production by monocyte derived cells of IFN which endogenously activates the cells (stress signal). This IFN induction can be generated
15 by double stranded RNA (such as poly IC) (polyinosinic-polycytidylic acid) or by bacterial or mycobacterial extracts and particularly bacterial type DNA or corresponding natural or chemically modified oligonucleotides.

The invention also relates to a process for the preparation of stimulated monocyte derived cells, comprising the following steps :

20 - preparation of monocyte derived cells according to the following method :

1) recovery of blood derived mononuclear cells directly from blood apheresis or from blood bag collection, followed if necessary by centrifugation, to eliminate a substantial part of red blood cells granulocytes and platelets, and collection of peripheral blood
25 leukocytes ;

2) washing peripheral blood leukocytes obtained at the preceding steps for instance by centrifugation (to remove 90% of platelets, red blood cells and debris) to obtain mononuclear cells ;

3) resuspension of the cells (monocytes + lymphocytes) obtained at
30 the preceding step in culture medium (AIM V, RPMI or IMDM type) at 10⁶ to 2.10⁷ cells/ml, possibly completed by cytokines and/or autologous serum, and culture for 5 to 10 days at 37°C under O₂/CO₂

atmosphere in hydrophobic gas permeable bags, to obtain monocyte derived cells and contaminating lymphocytes ;

- stimulation of said monocyte derived cells by addition of chemicals which induce endogenous IFN production such as double stranded RNA or bacterial or mycobacterial extracts and particularly bacterial type DNA or corresponding natural or chemically modified oligonucleotides.

It should be noted that the presence of contaminating lymphocytes with the monocyte derived cells during culture and differentiation of the monocytes allows a better control of stimulation and cell recovery through paracrine cellular interactions.

The lymphocytes are segregated from the stimulated monocytes derived cells at the end of the process.

The monocyte derived cells can be for instance prepared according to a method such as described in patents n° PCT/EP93/01232, n° WO94/26875 or EP 97/02703 or in the articles mentioned below:

. "Autologous lymphocytes prevent the death of monocytes in culture and promote, as do GM-CSF, IL-3 and M-CSF, their differentiation into macrophages". (Lopez M., Martinache Ch., Canepa S., Chokri M., Scotto F., Bartholeyns J.; J. of Immunological Methods, 159:29-38, 1993) ;

. "Immune therapy with macrophages: Present status and critical requirements for implementation" (Bartholeyns J., Romet-Lemonne J-L., Chokri M., Lopez M. ; Immunobiol., 195: 550-562, 1996) ;

. "In vitro generation of CD83⁺ human blood dendritic cells for active tumor immunotherapy" (Thurnher M., Papesh C., Ramoner R., Gastlt G. and al. ; Experimental Hematology, 25:232-237, 1997) ;

. "Dendritic cells as adjuvants for immune-mediated resistance to tumors" (Schuler G. and Steinman R. M. ; J. Exp. Med., 186:1183-1187, 1997).

The monocyte derived cells and contaminating lymphocytes can be treated so as to interiorize drugs, proteins or antigens, by culture of said monocyte derived cells and contaminating lymphocytes for 2 to 24 h, in the presence of drugs, proteins or antigens to interiorize these compounds in said monocyte derived cells.

In a particular embodiment of the invention, the process described above comprises, prior to the step of stimulation, a step of loading the monocyte derived cells with exogenous compounds such as drugs, proteins, growth factors of interest (e.g. by pinocytosis, phagocytosis of particular aggregates, diffusion), or with DNA coding for a protein of interest (i.e. with DNA plasmids, by sugar receptors mediated uptake for glycosylated polylysine-DNA or by lipid-DNA intake). The loaded monocyte derived cells are then stimulated by physical means such as described above, and more particularly by electropulsation which causes the transport of the exogenous compound loaded from the cytoplasm to the nuclei (where they can for example insert in DNA).

The process of the invention, in an advantageous embodiment, comprises, after the step of stimulation, the additional step of centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C, and resuspension, for instance in isotonic medium containing autologous serum.

The process of the invention, according to another advantageous embodiment, comprises, after the step of stimulation, the additional steps of:

- centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C, and resuspension, for instance in isotonic medium containing autologous serum, and

- freezing at a temperature at least of -80°C aliquots of the stimulated monocyte derived cells obtained at the preceding step, with the addition of a cryopreservative such as polyethyleneglycol, glycerol, DMSO (dimethylsulfoxide).

According to an advantageous embodiment, the process for the preparation of stimulated monocyte derived cells according to the invention, comprises the following steps:

- loading the monocyte derived cells thus obtained with an exogenous nucleic acid through endocytosis targeting their mannose and/or Fc receptors, or via pinocytosis of macromolecular nucleic acid aggregates, and

- submission of the monocyte derived cells obtained at the preceding step to physical stress such as electropulsation, for example about 1 to about 10 pulses of about 5 msec at about 0.3 to about 1 kV/cm, enabling intracellular transfer of the exogenous nucleic acid into the nucleus and integration into the DNA of the nucleus.

According to another advantageous embodiment of the invention, the process for the preparation of stimulated monocyte derived cells comprises the following steps:

- preparation of monocyte derived cells according to the following method :

5 1) recovery of blood derived mononuclear cells directly from blood apheresis or from blood bag collection, followed if necessary by centrifugation, to eliminate a substantial part of red blood cells granulocytes and platelets, and collection of peripheral blood leukocytes ;

10 2) washing peripheral blood leukocytes obtained at the preceding steps for instance by centrifugation (to remove 90 % of platelets, red blood cells and debris) to obtain mononuclear cells ;

15 3) resuspension of the total mononuclear cells (monocytes + lymphocytes) obtained at the preceding step in culture medium (AIM-V, RPMI or IMDM type) at 10^6 to $2 \cdot 10^7$ cells/ml, possibly completed by cytokines and/or autologous serum, and culture for 5 to 10 days at 37°C under O_2/CO_2 atmosphere in hydrophobic gas permeable bags, to obtain monocyte derived cells and contaminating lymphocytes ;

20 - loading the monocyte derived cells thus obtained with an exogenous nucleic acid through endocytosis targeting their mannose and/or Fc receptors, or via pinocytosis of macromolecular nucleic acid aggregates, and

 - submission of the monocyte derived cells obtained at the preceding step to physical stress such as electropulsation, enabling intracellular transfer of the exogenous nucleic acid into the nucleus and integration into the DNA of the nucleus.

25 According to an advantageous embodiment of the invention, the process comprises, after the step of electropulsation, the additional step of centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C , and resuspension, for instance in isotonic medium containing autologous serum.

30 According to another advantageous embodiment of the invention, the process comprises, after the step of electropulsation, the additional steps of:

- centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C, and resuspension, for instance in isotonic medium containing autologous serum, and

- freezing at a temperature at least of -80°C aliquots of the stimulated monocyte derived cells obtained at the preceding step, with the addition of a cryopreservative such as polyethyleneglycol, glycerol, DMSO.

The invention also relates to stimulated monocyte derived cell such as obtained by the processes described above.

The invention also relates to a method for the *ex-vivo* stimulation of monocytes derived cells comprising physical stress. The stimulated cells, as measured by biological effects generated, enhance the immune response *in vivo* after reinjection to a patient.

The invention also relates to pharmaceutical compositions comprising, as active substance, stimulated monocyte derived cells as described above, in association with a pharmaceutically acceptable vehicle.

Advantageous pharmaceutical compositions according to the invention, are in the form of sterile injectable preparations or of sterile topical preparations.

In the injectable preparation, the active substance is present in an amount such that it corresponds from about 10^7 to about 10^{10} cells/kg of body weight, particularly from about 10^8 to about 10^9 . In a topical preparation, the active substance is present in an amount of about 10^5 to about 10^8 cells/cm² of body surface.

In particular embodiment, the monocyte derived cells are injected repeatedly at doses of 10^7 to $5 \cdot 10^9$ at intervals of 3 days to 6 months.

The injections can eventually be first local (subcutaneous, intramuscular, mucosal, in cavities or in tissues) and then systemic (intravenous or intralymphatic).

The invention also relates to pharmaceutical compositions as described above, in the form of a vaccine comprising, as active substance, stimulated monocyte derived cells as described above, having integrated in their nucleus an exogenous nucleic acid coding for a polypeptide or protein which is immunogenic with respect to pathogens involved in the pathology to be treated.

The invention also relates to the use of stimulated monocyte derived cells of the invention, for the preparation of a medicament for the treatment of tissue repair

The invention also relates to a method for the treatment of tissue repair comprising the use of stimulated monocyte derived cells as described above.

5 The invention also relates to the use of stimulated monocyte derived cells of the invention, for the preparation of a vaccine against tumours or infectious agents, or of a medicament for treating polypeptide or protein deficiency in a patient, said use comprising for instance the preparation of sterile flasks of stimulated monocyte derived cells suspension and their repeated local application on the injured site.

10 The invention also relates to a method for the vaccination against tumours or infectious agents comprising the use of stimulated monocyte derived cells of the invention, with said stimulated monocyte derived cells having integrated in their nucleus an exogenous nucleic acid coding for a polypeptide or a protein which is immunogenic with respect to the above-mentioned tumor or infectious agent.

15 The invention also relates to a method for *ex vivo* gene therapy comprising the use of stimulated monocyte derived cells of the invention, with said stimulated monocyte derived cells having integrated in their nucleus an exogenous nucleic acid coding for a polypeptide or a protein which is deficient in a patient, said use comprising for instance the preparation of a sterile injectable suspension of stimulated monocyte derived cells and its repeated systemic and local injection.

20 The invention also relates to a method for the stimulation of monocyte derived cells comprising the preparation of stimulated monocyte derived cells as described above, and injection *in vivo* to a patient to stimulate the immune system as evidenced by release of mediators and other biological effects.

The invention will be further illustrated in the following detailed description.

25 *Ex vivo* stressing of monocytes derived cells (MDC) by physical treatment to induce a new desired stimulating biological activity

30 Human blood derived mononuclear cells are grown *ex vivo* in culture bags in defined medium. They are submitted to specific stimuli such as electropulsation, heating at 40°C to 50°C or heat shock, microwaves. The intensity and length of these treatments determines the physiological status achieved by the MDC (Monocytes Derived Cells).

Before physical treatment, the differentiated MDC have eventually phagocytosed specific compounds such as drugs, nucleic acids, polypeptides, chemokines or growth factors, and are loaded with these compounds to be processed and/or released when required. They have therefore gained *ex vivo* new specific potential that can then be exploited therapeutically by local or systemic reinjection to the patient from whom the original blood mononuclear cells were apherized. Thus the release of various factors artificially loaded or endogenously produced by stressed MDC which are themselves in an activated status, is controlled.

Methods and culture conditions are disclosed describing the physical treatments used and the specific MDCs functionalities obtained. The beneficial effects of these cells used for the adoptive therapy of specific diseases are described.

Monocytes-Macrophages or Macrophages-Dendritic cells- grown *ex vivo*, are subsequently stimulated by irradiation, electropulsation, or thermal stress for purpose of gaining new therapeutic stimulating potential - generally via controlled release of various factors either artificially loaded into or endogeneously produced by MDCs.

Monocytes derived cells can be obtained in large amounts ($> 10^9$ MDCs) after culture of mononuclear cells obtained from blood apheresis or from blood "buffycoats" containing peripheral blood leucocytes in plastic or hydrophobic bags (for example ethylene vinylacetate or Teflon) and in defined culture media (see PCT patent application n° PCT/FR96/00121).

These MDCs are differentiated after one week of culture. They are then exposed *in vitro* to physical stress.

In the present invention, the stress consists in the disturbance of the physical environment of the cells (change of oxygen/CO₂ concentration and pressure osmolality temperature change, electric stimulation, microwaves, ultrasonication...) which results in temporary modification of ion fluxes, activation of intracellular kinases, stimulation of stress proteins, flux of molecules (proteins, drugs, nucleic acids) from the cytoplasm to the nucleus.

The stimulated MDCs have therefore acquired new characteristics, as described above.

TABLE 1

5

FACTORS RELEASED BY STRESSED STIMULATED MDC

ENZYMES

Lyzosymes

Neutral proteases

Plasminogen activator

Collagenase

Elastase

Angiotensin-convertase

Acid hydrolases

Proteases

Lipases

Ribonucleases

Phosphatases

Glycosidases

Sulphatases

Arginase

COMPLEMENT COMPOUNDS

C1, 4, 2, 3 and 5

Factors B and D and Properdin

C1-inhibitor

C3b inactivator and β -1H

ENZYMES INHIBITORS(Antiproteases)

 α 1-antiprotease

Plasmin inhibitors

 α 2-macroglobulin

Plasminogen activator inhibitors

PROTEINS BINDING FE AND LIPIDS

Acidic isoferritins

Transferrin

Transcobalamin II

RADICAL OXYGEN

Superoxyde

Hydrogen peroxide

Hydroxyl radical

Hypohalous acids

BIOACTIVE LIPIDS

Arachidonic acid metabolites

Prostaglandins E2, F2 α

Prostacyclin

Thromboxane

Leukotrienes B4, C, D and E

Hydroxy-eicosatetraenoic acids
(including SRS-A)

Platelet activating factors

CYTOKINES, HORMONES

Endogenous pyrogens

Interleukins 1 α and β ₁Tumors necrosis factor α Interferons α and β ₁

Interleukin 6 and 8

Chemotactic factors for

Neutrophils

T lymphocytes

Monocytes

Fibroblasts

Heamatopoeietic Colony Stimulating
Factors forGranulocyte-Macrophages (GM-CSF)

Granulocytes (G-CSF)

Macrophages (M-CSF)

Erythropoietin

Growth factors

Fibroblast growth factor"platelet-derived growth factor"

Fibronectin
Laminin
Lipid transfer protein
Thrombospondin

Transforming growth factor α and β
Endothelial cell growth factor
Hormones
1 α , 25-Dihydroxyvitamin D3
Insulin-like activity
Thymosin B4
 β endorphin
Adrenocorticotrophic hormone

EXAMPLES

Four examples of ongoing developments and applications are described
hereafter.

a) In a particular embodiment of the invention, MDCs are obtained after one week of culture of cells with high phagocytic activity.

These MDCs are triggered by heating 30 minutes at 45°C to express and release growth factors, heat shock and stress proteins, chemokines and monokines. These cells added to cultures of human fibroblasts, of human osteoblasts as well as to cultures of human chondrocytes stimulate the proliferation of these different cells.

The activated MDCs are frozen in aliquots at -80°C (in 10% DMSO, 10% autologous serum or in polyethyleneglycol 10% autologous serum) and then used when needed. The concentration of polyethyleneglycol can be increased after fast defreezing of the aliquot to obtain cells included in a gel, which can be directly applied on wounds or tissues needing repair. *In vivo*, these triggered MDCs sustain regeneration of skin tissues presenting necrotic lesions.

The major portion of defrosted MDCs in 30% glycerol 20% autologous serum retains viability for at least 48 h in oxygenated conditions. When added at a 1/1 ratio to fibroblasts, they increase their proliferation. Application of 10⁶ MDCs onto skin punch lesions induced to nude mice is used to assess the effect of these human MDCs on the quality of cicatrisation and of the detersion (histology).

The present invention describes in particular an effective method to induce skin wound healing by local application of autologous macrophages or MDCs prepared

with the MAK Cell Processor (PCT/FR96/00121) and incorporated in an adequate pharmaceutical gel preparation. Macrophages actively initiate phagocytosis of tissue debris and contaminating bacteria. Simultaneously, they release locally for days/weeks growth factors and monokines stimulating epidermal and dermal tissue regeneration and skin repair. These monokines are measured by ELISA method.

In a particular embodiment of the invention the MDCs differentiated and recovered with a cell processor are resuspended in glucose, polyethyleneglycol or sugar polymers (i.e.: Dextran derivatives, heparins or heparan sulfate, mannose-6 phosphates...). These sugar or polyethyleneglycol polymers allow cryopreservation of macrophage preparations aliquoted for sequential use, and after local application they stabilise by complexation of the growth factors secreted by macrophages and release them on demand. For cryopreservation of the macrophages, 4% autologous serum and 10% DMSO or polyethylenglycol can advantageously be used.

In another embodiment, macrophages are preloaded *ex vivo* with one or several growth factors such as PDGF, EGF, FGF... or a drug to increase their wound healing potential.

In a particular embodiment, autologous macrophages are replaced for therapy by an allogenic macrophage cell line such as Mono Mac 6 (Ziegler Heitbrock et al. - "Distinct patterns of differentiation induced in the monocytic cell line Mono Mac 6", J. of Leucocyte Biol., Vol. 55, January 1994), appropriately differentiated under good manufacture practice conditions.

b) In another embodiment of the invention, the MDCs prepared according to the process described have interiorized tumor antigens of interest (by phagocytosis of tumor apoptotic bodies generated from tumor cells and containing in particular mitochondria and DNA are cultured during 4 h at 37°C with the MDCs) and are then submitted to the physical stress. Due to the induced presentation of the antigens at the same time as accessory and costimulation molecules, specific T cells are activated and do proliferate when cocultured with the MDCs. *In vitro* proliferation of lymphocytes is shown in the test of mixed lymphocyte proliferation.

Immunostimulation around the cells presenting the antigen of interest is demonstrated by the secretion of TH1 type cytokines (IL-12, IFN γ , IL-2) in the presence of stressed MDCs.

5 Vaccination against the antigen of interest is shown after the injection of 1 million of these stressed antigen loaded MDCs by subcutaneous route in mice which causes potent immune response (presence of antitumor antibodies and of antitumor cytotoxic T lymphocytes).

10 c) In a third embodiment of the invention, MDCs are loaded with nucleic acids through endocytosis during 4 h at 37°C of macromolecular nucleic acid mannosylated polylysine aggregates targeting their mannose receptors. After washing and resuspension at 5 millions cells/ml in isotonic sucrose medium, these cells are then submitted to short electropulsation stimuli (5 pulses of 5 msecs at 0.5 kV/cm)
15 allowing intracellular transfer of the nucleic acid from the cytoplasm into the cell nuclei and integration in DNA. These cells are then washed and injected in animal models. The cell expression and local release for several weeks of the polypeptides coded by the nucleic acids interiorised before *ex vivo* physical treatment is demonstrated by ELISA and FACS analysis (fluorescence cell analysis).

20 Conditions for uptake of polylysine-cDNA are 0.1 μ g/ml/ 10^8 cells for 4 h at 37°C, followed by 5 square electric pulses of 5 millisecc at 0.3 to 0.5 kV.

The very effective transfection ($\geq 20\%$ efficiency and high intensity of expression) allows prolonged expression and release of the protein of interest in the extracellular medium.

25 This technique will prove particularly effective in the long lasting replacement therapy for the treatment of generic deficiencies, for example of Factor VIII in haemophiliacs with Factor VIII deficiency.

MDCs injected in an autologous way survive for several months in tissues where the release of factor of therapeutic interest can be measured.

d) Stimulation of monocyte derived cells by chemicals

Maturation and stimulation of MD-APC (monocyte derived-antigen presenting cells).

MATERIAL AND METHODS

5 - Generation and maturation of MD-APC.

MD-APC are generated from total PBMC (Peripheral Blood Mononuclear Cells) obtained by apheresis and culture in AIM-V medium in the presence of GM-CSF (500UI/ml) and IL-13 (50 ng/ml). At day 7 of the culture, double stranded RNA (d.s.RNA) (30 µg/ml) is added to the culture and the cells are incubated for another 10 48 hours. Phenotypic characterization is performed by flow cytometry on a FACScalibur cytofluometer using the CellQuest software (Becton Dickinson, San Jose, CA).

 - Allogenic lymphocyte proliferation :

Serial dilutions (10^3 to 10^5) of mitomycin treated MD-APC are cultured in the 15 presence of 10^5 allogeneic responder T cells for 4 days. T cell proliferation is measured by BrdU incorporation.

RESULTS

 - Phenotypic maturation of MD-APC :

20 Upon d.s.RNA treatment, CD40, CD80, CD86 expression increases on MD-APC. Moreover CD83, which is completely absent from untreated MD-APC is clearly expressed on more than 80 % of cells cultured in the presence of d.s.RNA. In contrast, CD14 which is expressed on 70 % of the untreated cells, is absent from cells treated with d.s.RNA.

25 - Functional maturation of MD-APC :

 Upon d.s.RNA treatment, 20 times less MD-APC are required to observe the same level of T cell proliferation, as compared to untreated MD-APC indicating potent immunostimulatory properties.

 - Cytokine secretion :

30 IL-12 secretion by MD-APCs is increased at least 10 to 100 fold 48 hours after addition of d.s.RNA to the culture medium, which would favor TH1 type immune responses.

CLAIMS

1. Stimulated monocyte derived cells presenting the following characteristics:

5 1) - increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides, proteins or compounds:

- . PDGF (platelet derived growth factor)
- . IGF1 (insulin growth factor)
- . MDGF (macrophage derived growth factor)
- 10 . bFGF (basic fibroblast growth factor)
- . GM-CSF (granulocyte macrophage - colony stimulating factor)
- . heat shock or stress proteins,
- . chemokines and monokines such as IL12 and IFN γ
- . enzymes or enzyme inhibitors,
- 15 . complement components,
- . transfer proteins,
- . peroxides, NO (nitrous oxide),
- . bioactive lipids,
- . hormones,

20 and

- increased presence, on their membranes, with respect to normal monocyte derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40,

25 and/or

2) presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

2. Stimulated monocyte derived cells according to claim 1, presenting the
30 following characteristics :

1) increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides or proteins :

- . PDGF (platelet derived growth factor)
- . IGF1 (insulin growth factor)
- . MDGF (macrophage derived growth factor)
- . bFGF (basic fibroblast growth factor)
- . GM-CSF (granulocyte macrophage - colony stimulating factor)
- . heat shock or stress proteins, such as HSP70, HSP90, GP96,
- . chemokines and monokines such as IL12 and IFN γ

and

- increased presence, on their membranes, with respect to normal monocyte derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40,

and/or

2) presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

3. Stimulated monocyte derived cells according to claim 1 or 2, wherein the activation markers are present in an amount of at least about 1000 molecules/cells.

4. Stimulated monocyte derived cells, which present at least one of the following characteristics:

- increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides, proteins or compounds:

- . PDGF
- . IGF1
- . MDGF
- . bFGF
- . GM-CSF
- . heat shock or stress proteins

- . chemokines and monokines such as IL12 and IFN γ
- . enzymes or enzyme inhibitors
- . complement components
- . transfer proteins
- . peroxides, NO (nitrous oxide),
- . bioactive lipids
- . hormones

and

- increased presence, on their membranes, with respect to normal monocyte derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40.

5. Stimulated monocyte derived cells according to claim 3, which present at least one of the following characteristics:

- increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides or proteins :

- . PDGF
- . IGF1
- . MDGF
- . bFGF
- . GM-CSF
- . heat shock or stress proteins
- . chemokines and monokines such as IL-12 and IFN γ

and

- increased presence, on their membranes, with respect to normal monocyte derived cells, of one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, or CD40.

6. Stimulated monocyte derived cells, which present the characteristic of having integrated at least one exogenous nucleic in their nucleus in the absence of the monocyte derived cell division.

5 7. Stimulated monocyte derived cells according to anyone of claims 1 to 3, which present the following characteristics:

- increased release, with respect to normal monocyte derived cells, of at least one of the following polypeptides, proteins or compounds:

- 10 . PDGF
- . IGF1
- . MDGF
- . bFGF
- . GM-CSF
- . heat shock or stress proteins
- 15 . chemokines and monokines such as IL12 and IFN γ
- . enzymes or enzyme inhibitors
- . complement components
- . transfer proteins
- . peroxides, NO (nitrous oxide),
- 20 . bioactive lipids
- . hormones

- and increased presence, on their membranes, with respect to normal monocyte derived cells, of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, and CD40,

25 - and presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

30 8. Stimulated monocyte derived cells according to claims 1 to 3, which present the following characteristics :

- increased release with respect to normal monocyte derived cells of at least one of the following polypeptides or proteins :

- . PDGF
- . IGF1
- 5 . MDGF
- . bFGF
- . GM-CSF
- . heat shock or stress proteins
- . chemokines and monokines such as IL12 and IFN γ

10 - and increased presence on their membranes with respect to normal monocyte derived cells of at least one of the following activation markers : CD1 α , CD11a, CD80, CD83, CD86, MHC class I and MHC class II molecules, adhesins, or accessory molecules for immunostimulation such as ICAM, and CD40,

15 - and presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division.

20 9. Stimulated monocyte derived cells according to claims 4, 5, 7 or 8, wherein the polypeptides, proteins or compounds are released in an amount higher than about 1 pg/cell/hr and the activation markers are present in the range of about 10^3 to about 10^5 molecules/cell.

25 10. Process for the preparation of stimulated monocytes derived cells comprising the step of stimulation of said monocyte derived cells by physical means such as : thermal stress (heating at 40°C to 50°C for at least 30 minutes), pressure change (from about 1 bar to about 0,05 bar, or from about 1 bar to about 10 bars), microwaves, electric shock (about 1 to about 10 s at about 250 mV), or electropulsation.

30 11. Process for the preparation of stimulated monocyte derived cells, comprising the following steps:

- preparation of monocyte derived cells according to the following method :

1) recovery of blood derived mononuclear cells directly from blood apheresis or from blood bag collection, followed if necessary by centrifugation to eliminate a substantial part of red blood cells granulocytes and platelets, and collection of peripheral blood leukocytes ;

2) washing peripheral blood leukocytes obtained at the preceding steps for instance by centrifugation (to remove 90% of platelets, red blood cells and debris) to obtain mononuclear cells ;

3) resuspension of the cells (monocytes + lymphocytes) obtained at the preceding step in culture medium (AIM-V, RPMI or IMDM type) at 10^6 to $2 \cdot 10^7$ cells/ml, possibly completed by cytokines and/or autologous serum, and culture for 5 to 10 days at 37°C under O_2/CO_2 atmosphere in hydrophobic gas permeable bags, to obtain monocyte derived cells and contaminating lymphocytes ;

- stimulation of said monocyte derived cells by physical means such as : thermal stress (heating at 40°C to 50°C for at least 30 minutes), pressure change (from about 1 bar to about 0,05 bar, or from about 1 bar to about 10 bars), microwaves, electric shock (about 1 to about 10 s at about 250 mV), or electropulsation for a time sufficient to induce the above-mentioned characteristics.

12. Process for the preparation of stimulated monocyte derived cells, comprising the following steps :

- preparation of monocyte derived cells according to the following method :

1) recovery of blood derived mononuclear cells directly from blood apheresis or from blood bag collection, followed if necessary by centrifugation, to eliminate a substantial part of red blood cells granulocytes and platelets, and collection of peripheral blood leukocytes ;

2) washing peripheral blood leukocytes obtained at the preceding steps for instance by centrifugation (to remove 90% of platelets, red blood cells and debris) to obtain mononuclear cells ;

3) resuspension of the cells (monocytes + lymphocytes) obtained at the preceding step in culture medium (RPMI or IMDM type) at 10^6 to 2.10^7 cells/ml, possibly completed by cytokines and/or autologous serum, and culture for 5 to 10 days at 37°C under O₂/CO₂ atmosphere in hydrophobic gas permeable bags, to obtain monocyte derived cells and contaminating lymphocytes ;

- stimulation of said monocyte derived cells by addition of chemicals which induce endogenous IFN production such as double stranded RNA, or bacterial or mycobacterial extracts and particularly bacterial type DNA or corresponding natural or chemically modified oligonucleotides.

13. Process for the preparation of stimulated monocyte derived cells according to claim 11 or 12, comprising, before the step of stimulation, the step of culture of said monocyte derived cells and contaminating lymphocytes for 2 to 24 h, in the presence of drugs, proteins or antigens to interiorize these compounds in said monocyte derived cells.

14. Process for the preparation of stimulated monocyte derived cells according to claim 11 to 13, comprising the additional step of centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C, and resuspension, for instance in isotonic medium containing autologous serum.

15. Process for the preparation of stimulated monocyte derived cells according to claim 11 to 14, comprising the additional steps of :

- centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C, and resuspension, for instance in isotonic medium containing autologous serum, and

- freezing at a temperature at least of -80°C aliquots of the stimulated monocyte derived cells obtained at the preceding step, with the addition of a cryopreservative such as polyethyleneglycol, glycerol, DMSO (dimethylsulfoxide).

16. Process for the preparation of stimulated monocyte derived comprising the following steps :

- loading the monocyte derived cells thus obtained with an exogenous nucleic acid through endocytosis targeting their mannose and/or Fc receptors, or via pinocytosis of macromolecular nucleic acid aggregates, and

- submission of the monocyte derived cells obtained at the preceeding step to physical stress such as electropulsation, for example about 1 to about 10 pulses of about 5 msecs at about 0.3 to about 1 kV/cm, enabling intracellular transfer of the exogenous nucleic acid into the nucleus and integration into the DNA of the nucleus.

17. Process for the preparation of stimulated monocyte derived cells comprising the following steps:

- preparation of monocyte derived cells according to the following method :

1) recovery of blood derived mononuclear cells directly from blood apheresis or from blood bag collection, followed if necessary by centrifugation, to eliminate a substantial part of red blood cells granulocytes and platelets, and collection of peripheral blood leukocytes ;

2) washing peripheral blood leukocytes obtained at the preceeding steps for instance by centrifugation (to remove 90 % of platelets, red blood cells and debris) to obtain mononuclear cells ;

3) resuspension of the cells (monocytes + lymphocytes) obtained at the preceeding step in culture medium (AIM-V, RPMI or IMDM type) at 10^6 to $2 \cdot 10^7$ cells/ml, possibly completed by cytokines and/or autologous serum, and culture for 5 to 10 days at 37°C under O_2/CO_2 atmosphere in hydrophobic gas permeable bags, to obtain monocyte derived cells and contaminating lymphocytes ;

- loading the monocyte derived cells thus obtained with an exogenous nucleic acid through endocytosis targeting their mannose and/or Fc receptors, or via pinocytosis of macromolecular nucleic acid aggregates, and

- submission of the monocyte derived cells obtained at the preceeding step to physical stress such as electropulsation, enabling intracellular transfer of the exogenous nucleic acid into the nucleus and integration into the DNA of the nucleus.

5 18. Process for the preparation of stimulated monocyte derived cells according to claim 17, comprising, before the step of loading, the step of culture of said monocyte derived cells and contaminating lymphocytes for 2 to 24h, in the presence of drugs, proteins or antigens to interiorize these compounds in said monocyte derived cells.

10 19. Process for the preparation of stimulated monocyte derived cells according to claims 17 or 18, comprising the additional step of centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C, and resuspension, for instance in isotonic medium containing autologous serum.

15 20. Process for the preparation of stimulated derived cells, according to claim 17 or 18, comprising the additional steps of :

20 - centrifugation of the stimulated monocyte derived cells at a temperature enabling cell preservation, for instance at 4°C, and resuspension, for instance in isotonic medium containing autologous serum, and

- freezing at a temperature at least of -80°C aliquots of the stimulated monocyte derived cells obtained at the preceeding step, with the addition of a cryopreservative such as polyethyleneglycol, glycerol, DMSO.

25 21. Stimulated monocyte derived cells such as obtained by the process according to anyone of claims 10 to 20.

30 22. Pharmaceutical composition comprising, as active substance, stimulated monocyte derived cells according to anyone of claims 1 to 9, in association with a pharmaceutically acceptable vehicle.

23. Pharmaceutical composition according to claim 22, in the form of sterile injectable preparations or of sterile topical preparations.

5 24. Pharmaceutical composition according to anyone of claims 22 or 23, in the form of a vaccine comprising, as active substance, stimulated monocyte derived cells according to anyone of claims 1 to 3, 6 to 9, having integrated in their nucleus an exogenous nucleic acid coding for a polypeptide or protein which is immunogenic with respect to pathogens involved in the pathology to be treated.

10 25. Use of stimulated monocyte derived cells according to anyone of claims 1 to 9, for the preparation of a medicament for the treatment of tissue.

15 26. Use of stimulated monocyte derived cells according to anyone of claims 1 to 3, 6 to 9, for the preparation of a vaccine against tumours or infectious agents, or of a medicament for treating polypeptide or protein deficiency in a patient.

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/EP 99/02106

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N5/06 A61K35/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BARTOLEYNS J ET AL: "IMMUNE THERAPY WITH MACROPHAGES: PRESENT STATUS AND CRITICAL REQUIREMENTS FOR IMPLEMENTATION" IMMUNOBIOLOGY, vol. 195, no. 4/05, October 1996, pages 550-562, XP002039948 see abstract	1
X	BARTHOLEYNS J, LOPEZ M: "IMMUNE CONTROL OF NEOPLASIA BY ADOPTIVE TRANSFER OF MACROPHAGES: POTENTIALLY FOR ANTIGEN PRESENTATION AND GENE TRANSFER" ANTICANCER RESEARCH, vol. 14, no. 6B, November 1994, pages 2673-2676, XP000608444 see the whole document --- -/--	1, 4-8, 22-26

☒

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 July 1999

Date of mailing of the international search report

12/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

Inter: nat Application No

PCT/EP 99/02106

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OKAMOTO H ET AL: "POSSIBLE INVOLVEMENT OF ADENOSINE 3':5'-CYCLIC MONOPHOSPHATE AND EXTRACELLULAR CALCIUM IONS IN HISTAMINE STIMULATION OF INTERLEUKIN-1 RELEASE FROM MACROPHAGE-LIKE P388D1 CELLS" IMMUNOLOGY, vol. 70, no. 2, June 1990, pages 186-190, XP000608448 see the whole document	1,4-8, 22-26
A	WO 92 05793 A (MEDAREX INC) 16 April 1992 see abstract	16
X	WO 94 26875 A (IDM IMMUNO DESIGNED MOLECULES) 24 November 1994	1,9
Y	see abstract see page 13, line 25 - page 16, line 28 * claims * see figure 1	10,11, 13-16
X	POLLA B.S. ET AL.: "Differential induction of stress proteins and functional of heat shock in human phagocytes" INFLAMMATION, vol. 19, no. 3, 1995, pages 363-378, XP002078002 us cited in the application	1,10
Y	see abstract	10,11, 13-16
X	MARIETHOZ E. ET AL.: "Exposure of monocytes to heat shock does not increase class II expression but modulates antigen-dependent T cell responses" INTERNATIONAL IMMUNOLOGY, vol. 6, no. 6, 1994, pages 925-930, XP000572866 UK see abstract	1,10
X	EP 0 808 897 A (IDM IMMUNO DESIGNED MOLECULES) 26 November 1997	1,4,6-8, 25,26
A	see the whole document	16,22-26
X	WO 96 22781 A (IDM IMMUNO DESIGNED MOLECULES) 1 August 1996 see abstract see page 13, line 19 - line 25 * examples, claims *	1

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02106

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 10002 A (UNIV FORDHAM) 20 March 1997	10, 11, 13-16
A	see abstract see page 1, line 10 - line 30 see page 2, line 31 - page 5, line 11 see page 6, line 26 - page 7, line 29 see page 11, line 9 - page 12, line 14 * examples, claims *	1, 2, 22-26
X	WO 97 21444 A (BALAZOVSKY MARK BORISOVICH ;KOZHEMYAKIN LEONID ANDREEVICH (RU)) 19 June 1997 see abstract see example 1	12
A	WO 92 21691 A (ERBA CARLO SPA) 10 December 1992 see abstract see page 25, line 1 - page 26, line 21 see claims	12
A	WO 82 02338 A (LERNER MARTIN A) 22 July 1982 see abstract see page 4, line 35 - page 6, line 26 see claims	12
A	PATENT ABSTRACTS OF JAPAN vol. 016, no. 289 (C-0956), 26 June 1992 & JP 04 077431 A (KANEBO LTD), 11 March 1992 see abstract	12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02106

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9205793 A	16-04-1992	AT 175118 T AU 667460 B AU 8869491 A CA 2093022 A DE 69130709 D EP 0553244 A ES 2129029 T JP 6502410 T	15-01-1999 28-03-1996 28-04-1992 06-04-1992 11-02-1999 04-08-1993 01-06-1999 17-03-1994
WO 9426875 A	24-11-1994	AU 701147 B AU 8050494 A DE 9390311 U JP 8510118 T US 5662899 A	21-01-1999 12-12-1994 09-05-1996 29-10-1996 02-09-1997
EP 0808897 A	26-11-1997	AU 2961597 A CA 2252505 A WO 9744441 A EP 0925356 A	09-12-1997 27-11-1997 27-11-1997 30-06-1999
WO 9622781 A	01-08-1996	FR 2729570 A AU 4626596 A CA 2210449 A EP 0806959 A US 5804442 A	26-07-1996 14-08-1996 01-08-1996 19-11-1997 08-09-1998
WO 9710002 A	20-03-1997	AU 6973596 A EP 0857068 A	01-04-1997 12-08-1998
WO 9721444 A	19-06-1997	RU 2089179 C AU 1113097 A AU 6839196 A CA 2239874 A CN 1207683 A EP 0869809 A WO 9721443 A	10-09-1997 03-07-1997 03-07-1997 19-06-1997 10-02-1999 14-10-1998 19-06-1997
WO 9221691 A	10-12-1992	EP 0541742 A JP 6500568 T	19-05-1993 20-01-1994
WO 8202338 A	22-07-1982	US 4389395 A EP 0069147 A	21-06-1983 12-01-1983